Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Object of the Study
2.2. Laboratory Methods
2.3. Instrumental Methods
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Cleland, J.G.; Tendera, M.; Adamus, J.; Freemantle, N.; Polonski, L.; Taylor, J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J. 2006, 27, 2338–2345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pfeffer, M.A.; Shah, A.M.; Borlaug, B.A. Heart Failure with Preserved Ejection Fraction in Perspective. Circ. Res. 2019, 124, 1598–1617. [Google Scholar] [CrossRef] [PubMed]
- Owan, T.E.; Hodge, D.O.; Herges, R.M.; Jacobsen, S.J.; Roger, V.L.; Redfield, M.M. Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction. N. Engl. J. Med. 2006, 355, 251–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, D.S.; Gona, P.; Albano, I.; Larson, M.G.; Benjamin, E.J.; Levy, D.; Kannel, W.B.; Vasan, R.S. A Systematic Assessment of Causes of Death After Heart Failure Onset in the Community. Circ. Heart Fail. 2011, 4, 36–43. [Google Scholar] [CrossRef] [Green Version]
- Stroev, Y.I.; Kaminova, O.M.; Serdyuk, I.Y.; Nitsa, N.A.; Chesnokov, L.P.; Churilov, L.P. Immunoendocrine interactions in acute and chronic diseases as a manifestation of typical conflict between systemic and local regulation [in Russian]. Tavricheskiy Med.-Biol. Vestnik 2012, 15, 230–232. [Google Scholar]
- Aksenova, T.A. Immunological disorders and endothelial dysfunction as predictors of development of left ventricular hypertrophy in hypertensive patients. Klin. Lab. Diagn. 2013, 8, 18–20. (In Russian) [Google Scholar]
- Kuzmin, A.G.; Gorbunov, V.V.; Goryainova, E.V.; Bogatikov, E.V.; Koshevaya, O.D. Changes in the content of some cytokines during chronic heart failure. Kazan Med. J. 2012, 93, 494–498. (In Russian) [Google Scholar] [CrossRef]
- Бapcyкoв, A.B.; Seidova, A.Y.; Гopдиенкo, A.B.; Cepгeeв, A.И.; Leychinsky, S.V.; Лейчинский, C.B. Hypertension and Chronic Heart Failure with Preserved Left Ventricular Ejection Fraction: Focus on Gender-Specific Features of the Proinflammatory Status. Arterial Hypertension 2017, 23, 457–467. (In Russian) [Google Scholar] [CrossRef]
- Jahan, A.; Ullah, M. The Cytokines and Heart Failure–A Review. Cardiovasc. J. 2011, 3, 200–212. [Google Scholar] [CrossRef]
- Esser, N.; Legrand-Poels, S.; Piette, J.; Scheen, A.J.; Paquot, N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pr. 2014, 105, 141–150. [Google Scholar] [CrossRef] [Green Version]
- Ruijter, H.D.; Pasterkamp, G.; Rutten, F.H.; Lam, C.S.P.; Chi, C.; Tan, K.H.; Van Zonneveld, A.J.; Spaanderman, M.; De Kleijn, D.P. Heart failure with preserved ejection fraction in women: The Dutch Queen of Hearts program. Neth. Heart J. 2015, 23, 89–93. [Google Scholar] [CrossRef] [PubMed]
- Ortona, E.; Pierdominici, M.; Maselli, A.; Veroni, C.; Aloisi, F.; Shoenfeld, Y. Sex-based differences in autoimmune diseases. Ann. Ist. Super. Sanita 2016, 52, 205–212. [Google Scholar] [PubMed]
- Chazova, I.E.; Zhernakova, Y.V. Diagnosis and treatment of arterial hypertension [Guidelines]. Syst. Hypertens. 2019, 16, 6–31. [Google Scholar] [CrossRef]
- Williams, B.; Mancia, G.; Spiering, W.; Rosei, E.A.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.F.; et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018, 39, 3021–3104. [Google Scholar] [CrossRef]
- Mareev, V.I.; Fomin, I.V.; Ageev, F.T.; Arutyunov, G.P.; Begrambekova, Y.L.; Belenkov, Y.N.; Vasyuk, Y.A.; Galyavich, A.S.; Garganeeva, A.A.; Gendlin, G.E.; et al. Clinical recommendations. Chronic heart failure (CHF). Russ. Heart Fail. J. 2017, 18, 3–40. [Google Scholar] [CrossRef]
- Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, J.S.C.; Falk, V.; González-Juanatey, J.R.; Harjola, V.-P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail. 2016, 18, 891–975. [Google Scholar] [CrossRef]
- Otterstad, J.E. Measuring left ventricular volume and ejection fraction with the biplane Simpson’s method. Heart 2002, 88, 559–560. [Google Scholar] [CrossRef]
- Devereux, R.B.; Alonso, D.R.; Lutas, E.M.; Gottlieb, G.J.; Campo, E.; Sachs, I.; Reichek, N. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 1986, 57, 450–458. [Google Scholar] [CrossRef]
- Aurigemma, G.; Chirinos, J.; Galderisi, M.; Gottdiener, J.; Haluska, B.; Ofili, E.; Marwick, T.H.; Gillebert, T.C.; Derumeaux, G.; Segers, P.; et al. Recommendations on the use of echocardiography in adult hypertension: A report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)†. Eur. Heart J. 2015, 16, 577–605. [Google Scholar] [CrossRef] [Green Version]
- Lang, R.M.; Bierig, M.; Devereux, R.B.; Flachskampf, F.A.; Foster, E.; Pellikka, P.A.; Picard, M.H.; Roman, M.J.; Seward, J.; Shanewise, J.S.; et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005, 18, 1440–1463. [Google Scholar] [CrossRef]
- Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015, 16, 233–271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Virani, S.S.; Alonso, A.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation 2020, 141, e139–e596. [Google Scholar] [CrossRef] [PubMed]
- Deswal, A.; Petersen, N.J.; Feldman, A.M.; Young, J.B.; White, B.G.; Mann, D.L. Cytokines and Cytokine Receptors in Advanced Heart Failure. Circulation 2001, 103, 2055–2059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scally, C.; Abbas, H.; Ahearn, T.; Srinivasan, J.; Mezincescu, A.; Rudd, A.; Spath, N.; Yucel-Finn, A.; Yuecel, R.; Oldroyd, K.; et al. Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy. Circulation 2019, 139, 1581–1592. [Google Scholar] [CrossRef] [PubMed]
- Zhazykbayeva, S.; Pabel, S.; Mügge, A.; Sossalla, S.; Hamdani, N. The molecular mechanisms associated with the physiological responses to inflammation and oxidative stress in cardiovascular diseases. Biophys. Rev. 2020, 12, 947–968. [Google Scholar] [CrossRef]
- Shi, W.; Ma, H.; Liu, T.; Yan, D.; Luo, P.; Zhai, M.; Tao, J.; Huo, S.; Guo, J.; Li, C.; et al. Inhibition of Interleukin-6/glycoprotein 130 signalling by Bazedoxifene ameliorates cardiac remodelling in pressure overload mice. J. Cell. Mol. Med. 2020, 24, 4748–4761. [Google Scholar] [CrossRef] [Green Version]
- Yan, W.; Dong, Z.-C.; Wang, J.-J.; Zhang, Y.-L.; Wang, H.-X.; Zhang, B.; Li, H.-H. Deficiency of the Immunoproteasome LMP10 Subunit Attenuates Angiotensin II-Induced Cardiac Hypertrophic Remodeling via Autophagic Degradation of gp130 and IGF1R. Front. Physiol. 2020, 11, 625. [Google Scholar] [CrossRef]
- Tsoi, L.; Polupanov, A.; Sabirov, I.; Zalova, T.; Rysmatova, F.; Tsoy, L. Predictors of left ventricular hypertrophy development in patients with essential hypertension: Role of pro- and anti-inflammatory cytokines. Heart Vessels Transplant. 2018, 2, 97. [Google Scholar] [CrossRef]
- El Missiri, A.; Alzurfi, A.; Keddeas, V. The Relationship between Tumor Necrosis Factor Alpha and Left Ventricular Diastolic Function. J. Cardiovasc. Echogr. 2020, 30, 62. [Google Scholar] [CrossRef]
- Wu, C.; Huang, Y.-T.; Lin, H.-H.; Yang, C.-Y.; Lien, Y.-C.; Lee, J.-K.; Huang, J.-W.; Hung, K.-Y. Dissecting the Mechanisms of Left Ventricular Diastolic Dysfunction and Inflammation in Peritoneal Dialysis Patients. PLoS ONE 2013, 8, e62722. [Google Scholar] [CrossRef] [Green Version]
- De Mattos, A.M.; Ovidio, P.P.; Jordão, A.A.; Da Costa, J.A.C.; Chiarello, P.G. Association of Body Fat with Inflammation in Peritoneal Dialysis. Inflammation 2013, 36, 689–695. [Google Scholar] [CrossRef] [PubMed]
- Pedrinelli, R.; Dell’Omo, G.; Di Bello, V.; Pellegrini, G.; Pucci, L.; Del Prato, S.; Penno, G. Low-Grade Inflammation and Microalbuminuria in Hypertension. Arter. Thromb. Vasc. Biol. 2004, 24, 2414–2419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsioufis, C.; Stougiannos, P.; Kakkavas, A.; Toutouza, M.; Mariolis, A.; Vlasseros, I.; Stefanadis, C.; Kallikazaros, I. Relation of Left Ventricular Concentric Remodeling to Levels of C-Reactive Protein and Serum Amyloid A in Patients With Essential Hypertension. Am. J. Cardiol. 2005, 96, 252–256. [Google Scholar] [CrossRef] [PubMed]
- Watanabe, T.; Yasunari, K.; Nakamura, M.; Maeda, K. Carotid artery intima-media thickness and reactive oxygen species formation by monocytes in hypertensive patients. J. Hum. Hypertens. 2006, 20, 336–340. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bielecka-Dąbrowa, A.; Michalska-Kasiczak, M.; Gluba-Brzózka, A.; Ahmed, A.; Gerdts, E.; Von Haehling, S.; Rysz, J.; Banach, M. Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension. Sci. Rep. 2015, 5, 8916. [Google Scholar] [CrossRef] [Green Version]
- Kong, P.; Christia, P.; Frangogiannis, N.G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 2014, 71, 549–574. [Google Scholar] [CrossRef] [Green Version]
- Gyöngyösi, M.; Winkler, J.; Ramos, I.; Do, Q.; Firat, H.; McDonald, K.; González, A.; Thum, T.; Díez, J.; Jaisser, F.; et al. Myocardial fibrosis: Biomedical research from bench to bedside. Eur. J. Heart Fail. 2017, 19, 177–191. [Google Scholar] [CrossRef]
Parameters | Males (n = 55) | Females (n = 49) | p Value |
---|---|---|---|
Age, years | 53.7 ± 6.4 | 51.5 ± 6.2 | 0.19 |
BMI, kg/m2 | 33.6 ± 5.2 | 30.3 ± 3.6 | 0.12 |
HbA1c, % | 6.08 ± 0.09 | 5.92 ± 0.08 | 0.39 |
NT-proBNP, pg/mL | 287 ± 96.9 | 282 ± 105 | 0.84 |
The 6 min walk test, m | 407 ± 74 | 420 ± 80 | 0.14 |
Office SBP, mmHg | 156 ± 8.8 | 148 ± 6.4 | 0.18 |
Office DBP, mmHg | 90.2 ± 4.4 | 85.5 ± 5.7 | 0.32 |
Heart rate, bpm | 74.3 ± 12.5 | 76.1 ± 8.7 | 0.21 |
Ejection fraction, % | 62.8 ± 0.68 | 61.6 ± 0.73 | 0.27 |
LVMI, g/m2 | 128 ± 1.52 | 121 ± 1.17 | 0.03 |
LAVI, mL/m2 | 36.7 ± 0.36 | 36.1 ± 0.34 | 0.24 |
E/e’ | 9.85 ± 0.40 | 8.63 ± 0.38 | 0.03 |
e’ averaged, cm/s | 7.41 ± 0.23 | 8.31 ± 0.24 | 0.009 |
CRP, mg/L | 4.91 ± 0.15 | 3.77 ± 0.17 | 0.001 |
TNF-α, pg/mL | 5.81 ± 0.24 | 4.74 ± 0.29 | 0.002 |
IL-6, pg/mL | 5.52 ± 0.29 | 4.21 ± 0.22 | 0.001 |
Parameters | Males (n = 55) | Females (n = 49) | ||
---|---|---|---|---|
r Coefficient | p-Value | r Coefficient | p-Value | |
LVMI, g/m2 | 0.600 | <0.001 | 0.603 | <0.001 |
RWT | 0.405 | <0.001 | 0.415 | <0.001 |
LAVI, mL/m2 | 0.728 | <0.001 | 0.567 | <0.001 |
e’, cm/s | −0.725 | <0.001 | −0.441 | <0.001 |
E/e’ | 0.641 | <0.001 | 0.417 | <0.001 |
Office SBP, mmHg | 0.655 | <0.001 | 0.535 | <0.001 |
Office DBP, mmHg | 0.470 | <0.001 | 0.415 | <0.001 |
6 min distance, m | −0.568 | <0.001 | −0.610 | <0.001 |
Parameters | Males (n = 55) | Females (n = 49) | ||
---|---|---|---|---|
r Coefficient | p-Value | r Coefficient | p-Value | |
LVMI, g/m2 | 0.538 | <0.001 | 0.393 | <0.001 |
RWT | 0.442 | <0.001 | 0.323 | 0.003 |
LAVI, mL/m2 | 0.653 | <0.001 | 0.457 | <0.001 |
e’, cm/s | −0.754 | <0.001 | −0.522 | <0.001 |
E/e’ | 0.719 | <0.001 | 0.393 | <0.001 |
Office SBP, mmHg | 0.746 | <0.001 | 0.431 | <0.001 |
Office DBP, mmHg | 0.598 | <0.001 | 0.333 | 0.003 |
6 min distance, m | −0.617 | <0.001 | −0.373 | 0.001 |
Parameters | Males (n = 55) | Females (n = 49) | ||
---|---|---|---|---|
r Coefficient | p-Value | r Coefficient | p-Value | |
LVMI, g/m2 | 0.596 | <0.001 | 0.569 | <0.001 |
RWT | 0.523 | <0.001 | 0.510 | <0.001 |
LAVI, mL/m2 | 0.665 | <0.001 | 0.606 | <0.001 |
e’, cm/s | −0.709 | <0.001 | −0.553 | <0.001 |
E/e’ | 0.636 | <0.001 | 0.450 | <0.001 |
Office SBP, mmHg | 0.670 | <0.001 | 0.596 | <0.001 |
Office DBP, mmHg | 0.532 | <0.001 | 0.520 | <0.001 |
6 min distance, m | −0.640 | <0.001 | −0.513 | <0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barsukov, A.V.; Seidova, A.Y.; Shcherbakova, K.A.; Black, M.S.; Korovin, A.E.; Churilov, L.P.; Tovpeko, D.V. Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study. Pathophysiology 2020, 27, 30-43. https://doi.org/10.3390/pathophysiology27010005
Barsukov AV, Seidova AY, Shcherbakova KA, Black MS, Korovin AE, Churilov LP, Tovpeko DV. Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study. Pathophysiology. 2020; 27(1):30-43. https://doi.org/10.3390/pathophysiology27010005
Chicago/Turabian StyleBarsukov, Anton V., Alla Yu. Seidova, Ksenia A. Shcherbakova, Marina S. Black, Alexander E. Korovin, Leonid P. Churilov, and Dmitry V. Tovpeko. 2020. "Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study" Pathophysiology 27, no. 1: 30-43. https://doi.org/10.3390/pathophysiology27010005
APA StyleBarsukov, A. V., Seidova, A. Y., Shcherbakova, K. A., Black, M. S., Korovin, A. E., Churilov, L. P., & Tovpeko, D. V. (2020). Systemic Action of Inflammatory Mediators in Patients with Essential Hypertension and Diastolic Chronic Heart Failure: A Clinical Pathophysiological Study. Pathophysiology, 27(1), 30-43. https://doi.org/10.3390/pathophysiology27010005